

Press release

Lund 22 March 2021

## Scandinavian ChemoTech is preparing for growth within veterinary medicine

***ChemoTech's subsidiary Vetiqure AB, which markets the Group's patented TSE technology for veterinary medicine, has successfully completed the recruitment of a product specialist.***

The product specialist will primarily focus on marketing and training veterinarians on the Swedish west coast, including Skåne, Småland, Blekinge and the rest of Scandinavia.

*"It feels good that we now can strengthen our efforts and seriously part in the great potential and needs that we see exist for vetIQure™. That we have also found a product specialist who loves to work in the field and has good experience of veterinary medicine is of course a great success "- says Anders Johnsson, Operations Manager for Vetiqure AB.*

*For further information please contact:*

Mohan Frick, CEO

+46 (0)10-218 93 00

[info@chemotech.se](mailto:info@chemotech.se)

***Certified Adviser: Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00,***

***E-mail: [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se)***

### **Scandinavian ChemoTech AB (publ)**

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: [www.chemotech.se](http://www.chemotech.se)